[Angiotensin receptor vaccines].

Hiroyuki Sasamura, Tatsuhiko Azegami, Hiroshi Itoh

研究成果: Review article査読

抄録

Recent clinical studies have shown that RAS inhibitors are effective not only for the prevention of end-organ damage in hypertensive patients, but also for prevention of new-onset hypertension, diabetes mellitus, and atrial fibrillation. Vaccines against the RAS have been developed since the 1950s, and a recent phase IIa placebo-controlled study has confirmed that an angiotensin vaccine causes a significant decrease in blood pressure in hypertensive patients. The results of animal experiments from our and other laboratories have suggested that vaccination against the angiotensin type 1 (AT1) receptor causes a significant decrease in blood pressure in animal models of hypertension, and also ameliorates hypertensive end-organ damage. The angiotensin receptor may therefore be an important target for the development of vaccines for the prevention of hypertension and related complications.

本文言語English
ページ(範囲)1633-1638
ページ数6
ジャーナルNihon rinsho. Japanese journal of clinical medicine
69
9
出版ステータスPublished - 2011 9 1
外部発表はい

ASJC Scopus subject areas

  • 医学(全般)

フィンガープリント

「[Angiotensin receptor vaccines].」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル